Skip to content
Stribild(elvitegravir)
Genvoya, Stribild, Vitekta (elvitegravir) is a small molecule pharmaceutical. Elvitegravir was first approved as Stribild on 2012-08-27. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
Combinations
Genvoya, Stribild
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cobicistat
+
Elvitegravir
+
Emtricitabine
+
Tenofovir alafenamide fumarate
Tradename
Company
Number
Date
Products
GENVOYAGilead SciencesN-207561 RX2015-11-05
1 products, RLD, RS
Cobicistat
+
Elvitegravir
+
Emtricitabine
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
STRIBILDGilead SciencesN-203100 RX2012-08-27
1 products, RLD, RS
Elvitegravir
Tradename
Company
Number
Date
Products
VITEKTAGilead SciencesN-203093 DISCN2014-09-24
2 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
genvoyaNew Drug Application2022-01-13
stribildNew Drug Application2021-09-16
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hiv infectionsEFO_0000764D015658B20
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Cobicistat / Elvitegravir / Emtricitabine / Tenofovir Alafenamide Fumarate, Genvoya, Gilead Sciences Inc
100397182032-10-06DP
87540652032-08-15DS, DPU-257
92967692032-08-15DS, DPU-257
86332192030-04-30DPU-257
81483742029-09-03DS, DPU-1279
98912392029-09-03DPU-257
76357042026-10-26DS, DPU-257
89811032026-10-26DS, DP
71762202026-08-27DS, DPU-257
73907912025-04-17DS, DP
Cobicistat / Elvitegravir / Emtricitabine / Tenofovir Disoproxil Fumarate, Stribild, Gilead Sciences Inc
85923972024-01-13DPU-257
87162642024-01-13DPU-257
94570362024-01-13DPU-257
97441812024-01-13DPU-257
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AJ: Integrase inhibitors, antiinfectives for systematic use
— J05AJ02: Elvitegravir
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR09: Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat
— J05AR18: Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat
HCPCS
No data
Clinical
Clinical Trials
41 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B202284319
HivD006678O98.72225415
Acquired immunodeficiency syndromeD000163EFO_0000765B20——31—4
Healthy volunteers/patients—1——1—2
Opioid-related disordersD009293EFO_0005611F11———1—1
Chronic hepatitis cD019698EFO_0004220B18.2———1—1
Metabolic bone diseasesD001851HP_0000938———1—1
CoinfectionD060085———1—1
Sleep wake disordersD012893G47———1—1
Immunosuppression therapyD007165———1—1
Show 1 more
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv-1D015497—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Insulin resistanceD007333EFO_00026141————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Job syndromeD007589EFO_0003775D82.4————11
Acute kidney injuryD058186HP_0001919N17————11
Chronic hepatitis bD019694EFO_0004197B18.1————11
Bone diseasesD001847M89.9————11
Sexually transmitted diseasesD012749A50-A64————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameELVITEGRAVIR
INNelvitegravir
Description
Elvitegravir is a quinolinemonocarboxylic acid that is 7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid substited at position 1 by a 1-hydroxy-3-methylbutan-2-yl group and at position 6 by a 3-chloro-2-fluorobenzyl group (the S-enantiomer). It is used in combination therapy for the treatment of HIV-1 infection. It has a role as a HIV-1 integrase inhibitor. It is a quinolinemonocarboxylic acid, an organofluorine compound, an aromatic ether, a quinolone and a member of monochlorobenzenes.
Classification
Small molecule
Drug classantivirals: integrase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1cc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C(=O)O)cn2[C@H](CO)C(C)C
Identifiers
PDB—
CAS-ID697761-98-1
RxCUI1306286
ChEMBL IDCHEMBL204656
ChEBI ID72289
PubChem CID5277135
DrugBankDB09101
UNII ID4GDQ854U53 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Stribild - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Genvoya - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3,126 documents
View more details
Safety
Black-box Warning
Black-box warning for: Genvoya, Stribild
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,216 adverse events reported
View more details